ClinicalTrials.gg
RecruitingNCT06580301Updated Feb 6, 2026

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of YK012 in B-cell Acute Lymphoblastic Leukemia, sponsored by Excyte Biopharma Ltd. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Excyte Biopharma Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Burkitt Lymphoma with a site in China — 58 open to participants now, 62 under way, 4 of them phase 3. Burkitt Lymphoma · China.

Planned enrollment
27th of 100
46 · median 24
Started
2024
with 17 others
Phase 1/2
21 of 102
9 open now
Primary completion
2026-12
later than 26 of 61 live
Registered
68th of 102
by date

Among the 102 studies in Burkitt Lymphoma with a site in China, this one is the 27th largest by planned enrollment of the 100 interventional ones that give a count, is one of 18 that started in 2024, is one of 21 in phase 1/2, reaches primary completion later than 26 of the 61 other live ones, and was the 68th registered.

Burkitt Lymphoma

977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

58 of the 102 studies in Burkitt Lymphoma with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 130 Burkitt Lymphoma studies recruiting now, 40 (31%) set no upper age limit and 77 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Burkitt Lymphoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).

Read the detailed description

YK012 is a bispecific antibody designed to link B cells and T cells resulting in T-cell activation and a cytotoxic T-cell response against cluster of differentiation (CD)19 expressing cells. Relapsed/refractory B-ALL in adult patients is an aggressive malignant disease with dismal prognosis. This study is designed in 2 parts as described below: Phase Ib (dose escalation) and Phase II (dose expansion). If in Phase Ib it is observed in adult subjects at doses with manageable risk and antitumor activity, studies in pediatric subjects can be initiated to explore safety and efficacy in pediatric subjects, as well as pharmacokinetic profiles.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants or their legally acceptable representative must sign an ICF indicating that the participants understand the purpose of, and procedures required for the study and are willing to participate in the study.
  2. Performance Status (ECOG) of 0-2.
  3. An estimated survival time of more than 12 weeks.
  4. A definitive diagnosis of CD19-positive B-cell acute lymphoblastic leukemia with any of the following conditions:

    1. Ph-negative B-ALL with any of the following: i. Failure to achieve complete remission after initial induction therapy. ii. Failure to achieve complete remission after salvage treatment. iii. Relapse with first remission duration ≤12 months. iv. Second or later relapse. v. Relapse after hematopoietic stem cell transplantation ().
    2. Ph-positive B-ALL: failure to 1 or more tyrosine kinase inhibitors (TKIs), or intolerance to treatment with TKIs, or with the T315I mutation.
  5. ≥ 5% blasts in the bone marrow by morphologic assessment.
  6. Recovery to Grade 0-1 (Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events () Version (v) 5.0) from adverse events related to prior therapy except alopecia.
  7. Adequate hematological and organ function.
  8. Female participants of must have a negative serum pregnancy test at screening. Female patients who are sexually active must use highly effective methods of throughout the study and for 3 months following the last dose of study treatment.
  9. Male participants must agree to use reliable methods of contraception (barrier methods or sexual abstinence) and avoid sperm donation throughout the study period and until 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Burkitt´s Leukemia according to World Health Organization (WHO) classification.
  2. History of antitumor therapy as follows, before the first dose of study drug:

    1. Targeted therapy with small molecule drug within 2 weeks or 5 half-lives, whichever is longer
    2. Targeted therapy with macromolecular drug or Immunomodulatory agent therapy within 3 weeks
    3. Radiotherapy or chemotherapy (except for intrathecal chemotherapy and dexamethasone), or treatment with Chinese traditional/patent medicine that has definite antitumor effect within 2 weeks
    4. Treatment with an drug within 4 weeks or 5 half-lives, whichever is shorter
    5. Receipt of any or live virus vaccine within 4 weeks
    6. stem cell transplantation within 6 weeks
    7. History of organ transplant, or allogeneic stem cell transplantation within 12 weeks.
  3. Any active acute (GvHD), grade 2-4 (according to Glucksberg criteria) or active chronic GvHD requiring systemic treatment.
  4. Other within 5 years, except localized malignancies that have been adequately treated or free of the disease for ≥ 5 years, e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-muscle invasive bladder cancer, localized prostate cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast.
  5. Active central nervous system (CNS) involvement or meningeal involvement with clinical signs, or other evidence of uncontrolled to the CNS or meninges, judged by the investigator.
  6. a. History of or current relevant CNS pathology as epilepsy, seizure, paresis, aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis. b. Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI.
  7. History or evidence of cardiovascular disease, including:

    1. Acute coronary syndromes (e.g., myocardial infarction, unstable angina)
    2. Coronary angioplasty or stenting within 6 months prior to enrollment
    3. unstable arrhythmias (e.g., atrial fibrillation), however, atrial fibrillation has been controlled for over 30 days prior to the first dose of YK012 were allowed
    4. (NYHA) stage III or higher congestive heart failure
    5. (LVEF) below lower limit of the study center, or LVEF\<50% if there is no lower limit at the study center
    6. The Fridericia- interval (QTcF, mean of triplicate measurements) ≥ 470 msec (female) or ≥ 450 msec (male)
    7. Implantable defibrillator
    8. Clinically uncontrollable hypertension (i.e., SBP≥160 mm Hg and/or DBP≥100 mm Hg).
  8. Known allergy to monoclonal antibody drugs or exogenous immunoglobulin.
  9. History of CD19 targeted therapy and positive test result for immunogenicity of YK012 at screening.
  10. Any major organ surgery or significant trauma within 4 weeks prior to the first dose of YK012, or those requiring elective surgeries during the study, and all AEs associated with surgery or significant trauma have not recovered to Grade ≤1 or baseline graded by v5.0 before the first dose of the YK012.
  11. Regular dose of systemic during 4 weeks prior to initiation of study drug, or anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent during the trial, or any other therapy within 4 weeks prior to study entry.
  12. Virological tests: virus surface antigen (HBsAg) positive and/or hepatitis B core antibody (HBcAb) positive, and hepatitis B virus (HBV) deoxyribonucleic acid (DNA)> of the testing agency; antibody (HCV-Ab) positive and hepatitis C virus-RNA (HCV-RNA)>ULN of the testing agency; Anti- (Anti-HIV) positive. Participants will be excluded from the study if any of the above criteria is met.
  13. Uncontrolled active infections requiring oral or intravenous systemic therapy, except for local treatment.
  14. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently).
  15. Pregnant or lactating women.
  16. Known mental disorder that may affect study compliance or poor compliance.
  17. Other serious systemic diseases or laboratory abnormalities or other reasons that the investigator believes are not appropriate for participating in the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    YK012

    Participants will be assigned to a dose level of YK012 based on when the participants join this study. Participants will receive YK012 by intravenous infusion (IV), once per week, four weeks per treatment cycle.

    Drug: YK012

Interventions

  • DrugYK012

    The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.

    Also known as: YK012 for Injection

06

What researchers measure

Primary outcomes

  1. The Incidence and Profile of Dose-limiting Toxicity (DLT)

    The toxicities occurring within 28 days (i.e., DLT observation period) after the first dose will be defined as DLTs in the discretion of the investigator as related to the IMP (Investigational Medicinal Product). This outcome measure is applicable for dose escalation phase only. The MTD dose will be calculated by the statistician upon completion of the dose escalation study.

    Time frame: 28 days after the first dose

  2. Maximum Tolerated dose (MTD) or The Recommended Dose for Future Clinical Study

    This outcome measure is applicable for dose escalation phase only. The MTD dose will be calculated by the statistician upon completion of the dose escalation study.

    Time frame: Through study completion, 20 weeks

  3. Number of Participants with Adverse Events

    An AE is defined as any untoward medical event that occurs after a subject receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the investigational drug.

    Time frame: From the time the participant signs the ICF until the end of the safety visit period, assessed up to 24weeks.

  4. Number of Participants with Serious Adverse Events

    An SAE refers to an untoward medical occurrence such as death, life-threatening event, permanent or serious disability or loss of function, need for hospitalization or prolongation of hospitalization after the subject receives the IMP, and congenital abnormalities or birth defects.

    Time frame: From the time the participant signs the ICF until the end of the safety visit period, assessed up to 24weeks.

  5. Dose Expansion Phase: Objective Response Rate (ORR)

    ORR is defined as percentage of participants achieving either a complete response (CR) or complete remission with partial hematological recovery (CRi). The MTD dose will be calculated by the statistician upon completion of the dose escalation study. This outcome measure is applicable for dose expansion phase only.

    Time frame: From the time the participant signs the ICF until hematological relapse, assessed up to 1 year

Secondary outcomes

  1. Area Under the Concentration-time Curve (AUC)

    The PK (AUC) of YK012 will be evaluated.

    Time frame: Up to 20 weeks

  2. Maximum Observed Concentration (Cmax)

    The PK (Cmax) of YK012 will be evaluated.

    Time frame: Up to 20 weeks

  3. Time to Reach Maximum Concentration (Tmax)

    The PK (Tmax) of YK012 will be evaluated.

    Time frame: Up to 20 weeks

  4. Half Life (t1/2) of YK012

    The PK (t1/2) of YK012 will be evaluated.

    Time frame: Up to 20 weeks

  5. Clearance (CL) of YK012

    The PK (CL) of YK012 will be evaluated.

    Time frame: Up to 20 weeks

  6. Trough Plasma Concentration (Ctrough)

    The PK (Ctrough) of YK012 will be evaluated.

    Time frame: Up to 20 weeks

  7. Percentage of Participants with Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab) Against YK012

    Assess the percentage of participants with ADA and Nab (only assessed when ADA positive except for the screening period) after treatment with YK012.

    Time frame: Up to 20 weeks

  8. Dose Escalation Phase: Objective Response Rate (ORR)

    ORR is defined as percentage of participants achieving either a complete response (CR) or complete remission with partial hematological recovery (CRi). The MTD dose will be calculated by the statistician upon completion of the dose escalation study. This outcome measure is applicable for dose escalation phase only.

    Time frame: From the time the participant signs the ICF until hematological relapse, assessed up to 1 year

  9. Relapse-free Survival (RFS)

    RFS was measured from first dose of YK012 until the first assessment of documented relapse, or death due to any cause, whichever occurs first including the time after the transplant.

    Time frame: From the time the participant signs the ICF until hematological relapse, assessed up to 1 year

  10. Overall survival (OS)

    Overall survival was measured from the first treatment with YK012 until death due to any cause. Participants who did not die were censored at their last contact date.

    Time frame: From the date of first dose until loss of follow-up, death, withdrawal of informed consent, or the end of study, whichever occurs first, assessed up to 1 year.

  11. Number of B cells and T cells in peripheral blood after administration

    Assess the number of B cells and T cells in peripheral blood after treatment with YK012

    Time frame: Up to 20 weeks

07

Study locations

12 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 30, 2024
StartActual
Sep 25, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06580301
Lead sponsor
Excyte Biopharma Ltd
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Sep 25, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Jie Jin, MD
Contact
jiej0503@163.com
+86-0571-87236898
Jie Jin, MD
principal investigator · Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YK012

Start the discussion